Proenkephalin A 119-159 (penKid) and mortality in stable patients at high cardiovascular risk
Open Access
- 2 September 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (9) , sfae246
Abstract
Proenkephalin A 119–159 (penKid) is a novel blood biomarker for real-time assessment of kidney function and was found to be independently associated with worsening kidney function and mortality. A novel penKid-based estimated glomerular filtration rate equation (eGFRPENK-Crea), outperforms current creatinine-based eGFR equations in predicting iohexol or iothalamate plasma clearance-based measured GFR. In this study, we aimed to evaluate the predictive value of penKid and eGFRPENK-Crea for all-cause mortality in stable patients at high cardiovascular risk. Circulating penKid levels were assessed in 615 stable patients hospitalized at the Department of Cardiology at University Hospital Aachen, Germany. The endpoint was all-cause mortality; follow up was 3 years. penKid levels were higher in 46 non-survivors [58.8 (IQR 47.5–85.0) pmol/l] compared to 569 survivors [43.8 (IQR 34.0–58.0) pmol/l; P < .0001]. Univariable Cox regression analyses found penKid and eGFRPENK-Crea to be associated with all-cause mortality (C index 0.703, χ2 33.27, P < .00001; C index 0.716, χ2 36.51, P < .00001). This association remained significant after adjustment for significant baseline parameters including age, smoking, chronic heart failure, use of diuretics, leucocytes, body mass index, sex, and creatinine (C index 0.799, χ2 72.06, P < .00001). Importantly, penKid provided significant added value on top of eGFRCKD-EPI 2021 (eGFRCKD-EPI 2021: C index 0.716, χ2 34.21; eGFRCKD-EPI 2021 + penKid: C index 0.727, χ2: 40.02; Delta χ2 5.81; all P < .00001) for all-cause mortality prediction in our cohort. penKid levels and eGFRPENK-Crea is associated with all-cause mortality within a 3-year follow-up period and the addition of penKid on top of eGFRCKD-EPI 2021 provided significant added value in mortality prediction.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (520275106)
- European Research Area Network on Cardiovascular Diseases (JTC-2019)
- European Foundation for the Study of Diabetes (NNF2OSA0066111)
- German Research Foundation (SFB TRR 219–322900939–M-07)
This publication has 11 references indexed in Scilit:
- Assessing GFR With ProenkephalinKidney International Reports, 2023
- PenKid measurement at admission is associated with outcome in severely ill burn patientsBurns, 2020
- Bioactive adrenomedullin, proenkephalin A and clinical outcomes in an acute heart failure settingOpen Heart, 2019
- Circulating Proenkephalin, Acute Kidney Injury, and Its Improvement in Patients with Severe Sepsis or ShockClinical Chemistry, 2018
- Analytical performance of an immunoassay to measure proenkephalinClinical Biochemistry, 2018
- Proenkephalin (PENK) as a Novel Biomarker for Kidney FunctionThe Journal of Applied Laboratory Medicine, 2017
- Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart FailureJournal of Cardiac Failure, 2017
- Proenkephalin and Prognosis After Acute Myocardial InfarctionJACC, 2014
- Proenkephalin expression and enkephalin release are widely observed in non-neuronal tissuesPeptides, 2008
- 3 Opiate receptors: Enkephalins and endorphinsClinics in Endocrinology and Metabolism, 1983